Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.

Medical oncology (Northwood, London, England) - 1 Sept 2017

Koizumi Tomonobu, Fukushima Toshirou, Gomi Daisuke, Kobayashi Takashi, Sekiguchi Nodoka, Mamiya Keiko, Tateishi Kazunari, Katou Akane, Oguchi Kazuhiro

Abstract excerpt

Recent advances in positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET) have facilitated not only the diagnosis and staging of lung cancer, but also the prediction of treatment outcome. The present study was designed to assess the usefulness of early FDG-PET examination for predicting subsequent tumor size reduction in response to molecular targeted agents in metastatic non-small cell lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crizotinib
Share to Fluorodeoxyglucose F18

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Molecular Targeted Therapy

Share to Positron-Emission Tomography

Share to Pyrazoles

Share to Pyridines

Share to Quinazolines

Source

Identifiers

PMID: 28864950
DOI: 10.1007/s12032-017-1032-0

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.PMID 28864950Read ↗

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.Semantic proximity Read ↗

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.Semantic proximity Read ↗

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.Semantic proximity Read ↗

Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer.Semantic proximity Read ↗

Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.Semantic proximity Read ↗

[<sup>18</sup>F]FDG PET/CT: Lung Nodule Evaluation in Patients Affected by Renal Cell CarcinomaSemantic proximity Read ↗

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.Semantic proximity Read ↗

Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.Semantic proximity Read ↗

Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.